Short Interest in CalciMedica Inc. (NASDAQ:CALC) Declines By 60.5%

Posted by Francis Steltz on Sep 14th, 2026

CalciMedica Inc. (NASDAQ:CALC – Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 127,684 shares, a decrease of 60.5% from the August 15th total of 323,241 shares. Based on an average daily volume of 99,862 shares, the days-to-cover ratio is presently 1.3 days. Currently, 2.6% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CALC. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Wall Street Zen downgraded CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Guggenheim assumed coverage on CalciMedica in a report on Thursday, August 20th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CalciMedica currently has a consensus rating of “Hold” and an average price target of $50.00.

Read Our Latest Stock Report on CalciMedica

Insider Transactions at CalciMedica

In other CalciMedica news, Director Fred A. Middleton purchased 49,794 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were purchased at an average price of $4.00 per share, for a total transaction of $199,176.00. Following the completion of the purchase, the director directly owned 212,654 shares of the company’s stock, valued at approximately $850,616. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 28.25% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CalciMedica

Several large investors have recently modified their holdings of CALC. Envestnet Asset Management Inc. raised its stake in shares of CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares during the period. Cetera Investment Advisers increased its position in shares of CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of CalciMedica by 26.1% in the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after buying an additional 18,300 shares during the last quarter. Jane Street Group LLC purchased a new stake in CalciMedica during the fourth quarter valued at about $127,000. Finally, Boothbay Fund Management LLC bought a new stake in CalciMedica in the 4th quarter worth approximately $506,000.

CalciMedica Trading Up 0.8%

CALC stock traded up $0.02 during trading on Monday, hitting $2.00. The company had a trading volume of 83,982 shares, compared to its average volume of 199,556. The business has a 50-day moving average of $3.31 and a 200-day moving average of $3.44. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67. CalciMedica has a one year low of $1.87 and a one year high of $36.00. The stock has a market cap of $13.63 million, a PE ratio of -0.29 and a beta of 0.83.

CalciMedica (NASDAQ:CALC – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. Research analysts predict that CalciMedica will post -5.25 earnings per share for the current fiscal year.

About CalciMedica

(Get Free Report)

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.